The translational and genomics biology group provides services that cater to the continuum of drug discovery programs in Immuno-oncology pertaining to translational and genomics aspects. We bring to the table experience across both small molecules and biologics, antibody discovery and Integrated research, development of new assays, developing translational models using human immune cells, phenotyping, and characterization. We have availability of human samples from healthy and diseased populations and a wide range of assays including target cell killing assays, immune cell activation, MLR, mast cell degranulation, neutrophil activation, and cytokine release assays. We also offer flow cytometry, live cell imaging, and multiplex platforms for biomarker studies. We are equipped with a 96 capillary DNA analyzer (ABI) for Sanger sequencing and two platforms (Illumina™ MiSeq and Illumina™ NextSeq) for next-generation sequencing (NGS).
Our NGS technology enables profiling of DNA and RNA at very high throughputs and high resolution to address a variety of biological questions. The technology can be exploited at early discovery stages (lead identification, target-discovery, validation, mechanism of action), as well as during later stages (in vitro/in vivo studies, tumor biology, PDx models, biomarker discovery, genome editing, CDx development, patient stratification for trial design, drug repurposing).
The Syngene NGS facility offers a range of sequencing services that include the following:
- Whole genome sequencing (de novo and resequencing)
- Targeted resequencing (custom amplicon panels)
- Exome sequencing
- Transcriptome sequencing
- ChIP-sequencing
- Microbiome sampling by 16s rDNA sequencing
- Whole genome shotgun metagenomics
Our services include initial experimental design, sample processing (library preparation), sequencing, and tiered analysis based on requirements of the client.
